Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania: A Controlled Randomised Trial

NCT03640403 is registered in ClinicalTrials.gov with National Institute for Medical Research, Tanzania as lead sponsor.

NCT NCT03640403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03640403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania: A Controlled Randomised Trial
Lead sponsor
National Institute for Medical Research, Tanzania
Phase
Phase 3
Overall status
Completed
Start date
March 26, 2019
Completion date
December 31, 2021
Enrollment
1,555 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, malaria,falciparum